Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas

Fig. 2

Kaplan Meyer survival curve displays the therapeutic effect of intratumoral bolus of TMZ administered at day 7 in C57BL/6 mice bearing the orthotopically syngeneic GL261 glioma. Log-rank test analysis showed significantly prolonged median survival in mice treated with 60 μg of TMZ (n = 12) compared with non-treated (n = 8). TMZ 60 μg injection vs. non-treated (*p = 0.0279). Survival was monitored for 100 days. Toxicity was present immediately after the injection in both highest doses 175 μg (2/6; 33%) and 60 μg (1/12; 8%) (pointed area)

Back to article page